How GLP-1 agonists work: Ozempic, Wegovy, Mounjaro and Zepbound, explained

TL;DR

• These drugs copy a gut hormone you already make - GLP-1, released after a meal, re-engineered to resist DPP-4 breakdown so it lasts about a week instead of minutes.
• Four famous brands, two molecules - Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide.
• Four effects follow - glucose-dependent insulin release, glucagon suppression, slowed gastric emptying and central appetite suppression.
• The first two are why this began as diabetes medicine; the second two are why it became weight medicine.
• Tirzepatide adds GIP - a second gut hormone that improves insulin sensitivity and is the reason it tends to outperform semaglutide head-to-head.
• The mechanism explains the downsides too - slowed gastric emptying is why nausea is the commonest side effect, and because the effect is maintained rather than curative, stopping tends to bring the weight back.

Educational content, not medical advice. Mechanism is explained for understanding, not as a how-to. No doses appear as instructions.

---

GLP-1 weight-loss drugs work by copying a hormone your gut already makes after a meal. That hormone - glucagon-like peptide-1, or GLP-1 - tells your body, in several ways at once, that you've eaten: it nudges insulin out in response to food, slows how fast your stomach empties, and signals the brain's appetite centres to feel full. The drugs are engineered versions that do the same thing but last about a week instead of minutes. That's the whole core idea. Everything else - Ozempic vs Wegovy vs Mounjaro, GLP-1 vs GIP - is detail layered on top of that one mechanism. Here's how it actually works.

The brand-name maze is really just two molecules

Before the biology, clear up the names, because the marketing makes this far more confusing than it is:

Four famous brands, two actual drugs. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide. The difference within each pair is the licensed use and dose; the difference between the pairs is how many gut-hormone pathways the molecule activates.

What GLP-1 actually does - the four effects

When a GLP-1 receptor agonist activates GLP-1 receptors around the body, four things follow - and together they explain both the blood-sugar and the weight effects:

The first two are why this class began as diabetes medicine. The second two - fullness and reduced appetite - are why it became the most effective weight medicine we've had. Same molecule, two jobs.

Why the drug lasts a week (and your own GLP-1 doesn't)

Your natural GLP-1 is broken down within minutes by an enzyme called DPP-4. The drugs are deliberately modified to resist that breakdown and to bind proteins in the blood, which is why a once-weekly injection can hold a steady effect. This is engineering, not an accident - and it's also why these aren't drugs that "wear off" between doses the way the natural hormone does.

What GIP adds (the tirzepatide difference)

Tirzepatide (Mounjaro/Zepbound) does everything above and adds a second gut hormone: GIP (glucose-dependent insulinotropic polypeptide). GIP appears to improve insulin sensitivity and influence how fat is handled, and - for reasons still being worked out - adding it seems to deliver more weight loss and sometimes better tolerability than GLP-1 alone. That second pathway is the entire reason tirzepatide tends to outperform semaglutide head-to-head. (A third pathway, glucagon, is what the investigational drug retatrutide adds on top - more on that here.)

The effect trials don't measure: "food noise"

One of the most striking things people describe isn't a number in any trial - it's the quieting of "food noise," the constant low-grade mental chatter about eating. Mechanistically it fits: these drugs act directly on appetite circuitry in the brain, not just the stomach. We flag it as patient-reported rather than a measured endpoint, but it's described so consistently that it's worth naming - and for many people it's what makes eating less feel effortless rather than like willpower.

Why "how it works" explains the side effects too

Understanding the mechanism demystifies the downsides. Slowed gastric emptying is also why nausea and fullness-related GI effects are the most common side effects - and why titrating the dose up slowly helps. That shared pathway is the whole reason why GLP-1 doses start low: the effect you want and the effect you don't travel together, and escalation exists to let the gut adapt. It is also why more is not automatically better - what dose–response actually looks like is a curve that rises and then flattens, with benefit and burden flattening at different rates. The same appetite suppression that drives weight loss is why losing it carelessly can cost muscle. And because the effect is maintained rather than curative, stopping tends to bring the weight back. The biology that makes these drugs work is the same biology behind their limits.

The bottom line - and where to start

GLP-1 drugs aren't exotic or mysterious: they amplify a normal post-meal signal so it lasts a week instead of minutes, producing fullness, less appetite and steadier blood sugar. Tirzepatide adds a second such signal (GIP) for more effect. Knowing this is genuinely useful - it tells you why titration matters, why muscle needs protecting, and why the plan for staying on or coming off is as important as starting. The mechanism is simple; using it well is where supervision earns its keep.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

Frequently asked questions

How does Ozempic work for weight loss? Ozempic (semaglutide) mimics the gut hormone GLP-1: it slows stomach emptying and acts on the brain's appetite centres so you feel full and eat less, while also steadying blood sugar. Wegovy is the same molecule at a higher, weight-specific dose.

What's the difference between how Ozempic and Mounjaro work? Ozempic/Wegovy (semaglutide) activate one pathway, GLP-1. Mounjaro/Zepbound (tirzepatide) activate two - GLP-1 and GIP - which is why tirzepatide generally produces more weight loss.

Why do these drugs cause nausea? Largely because they slow gastric emptying - the same effect that keeps you full longer. It's usually mild-to-moderate and concentrated during dose escalation, which is why titration is gradual.

Do GLP-1 drugs work without diet and exercise? They reduce appetite on their own, but the quality of the result - losing fat rather than muscle, and keeping it off - depends heavily on protein, resistance training and supervision.

Related reading

• Tirzepatide vs semaglutide vs retatrutide vs CagriSema - the compounds compared
• Cagrilintide as a GLP-1 bridge or stack - a different pathway (amylin)
• What the glucagon arm of retatrutide actually does - the third receptor added on top of GLP-1 and GIP
• Mounjaro vs Wegovy vs Ozempic - the brand names, untangled
• Losing fat, not muscle, on a GLP-1 - the mechanism's trade-off
• Why GLP-1 doses start low - the physiology behind slow escalation
• Is there a "sweet spot" dose? - what dose–response actually looks like

---

Educational content, not medical advice. GLP-1 and GIP medications are prescription-only and require physician supervision. Individual responses vary. Claims for the Malaysian market are subject to MAB requirements.

Primary references

• Vivre Labs Internal Clinical Reference: semaglutide and tirzepatide mechanism (GLP-1 / GIP receptor agonism; DPP-4-resistant design; once-weekly pharmacokinetics).
• Jastreboff AM, et al. SURMOUNT-1 (tirzepatide). N Engl J Med. 2022;387:205–216.
• Wilding JPH, et al. STEP 1 (semaglutide). N Engl J Med. 2021;384:989–1002.
• Aronne LJ, et al. SURMOUNT-5 (tirzepatide vs semaglutide). N Engl J Med. 2025.